Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.30 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2641530 | 0.77 | PTP4A3 (0.30) | PTP4A3PTP4A1 | |
| SCHEMBL5201639 | 0.77 | — | — | |
| SCHEMBL2901699 | 0.66 | KMT2A (0.40) | HPGDLMNA | |
| SCHEMBL6643716 | 0.65 | ERN1 (0.39) | POLBHTT | |
| SCHEMBL2898740 | 0.65 | TSHR (0.44) | — | |
| SCHEMBL5204690 | 0.64 | MAPT (0.34) | HPGDLMNAHTT | |
| SCHEMBL2904257 | 0.64 | MAPT (0.34) | HPGDLMNAHTT | |
| SCHEMBL5187578 | 0.62 | — | — | |
| SCHEMBL5177426 | 0.62 | — | — | |
| SCHEMBL5187579 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4751557-B2 | — | — | 2011-08-17 | — | — | JP | claimed |
| EP-1278717-B1 | ONE-POT SYNTHESIS OF ALKYL 3-CYCLOPROPYLAMINO-2- 2,4-DIBROMO-3-(DIFLUOROMETHOXY)BENZOYL|-2-PROPENOATE AS A USEFUL INTERMEDIATE FOR ANTIBACTERIAL QUINOLONE MEDICAMENTS | RANBAXY LAB LTD (IN) | 2007-06-06 | — | — | EP | claimed |
| EP-1278717-A4 | ONE-POT SYNTHESIS OF ALKYL 3-CYCLOPROPYLAMINO-2- 2,4-DIBROMO-3-(DIFLUOROMETHOXY)BENZOYL]-2-PROPENOATE AS A USEFUL INTERMEDIATE FOR ANTIBACTERIAL QUINOLONE MEDICAMENTS | RANBAXY LAB LTD (IN) | 2005-06-08 | — | — | EP | claimed |
| US-20040267019-A1 | ONE-POT SYNTHESIS OF ALKYL 3-CYCLOPROPYLAMINO -2-[2,4-DIBROMO-3-(DIFLUROMETHOXY) BENZOYL]-2-PROPENOATE AS A USEFUL INTERMEDIATE FOR ANTIBACTERIAL QUINOLONE MEDICAMENTS | TOYAMA CHEMICAL COMPANY, LIMITED (JP) | 2004-12-30 | — | — | US | claimed |
| US-6835848-B1 | Reacting 2,4-dibromo-3-(difluoromethoxy)benzoic acid with a halogenating agent to get a corresponding acid chloride, then reacting with a 3-(dialkylamino)acrylic acid alkyl ester and then cyclopropylamine | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-28 | — | — | US | claimed |
| EP-1278717-A1 | ONE-POT SYNTHESIS OF ALKYL 3-CYCLOPROPYLAMINO-2- 2,4-DIBROMO-3-(DIFLUOROMETHOXY)BENZOYL]-2-PROPENOATE AS A USEFUL INTERMEDIATE FOR ANTIBACTERIAL QUINOLONE MEDICAMENTS | Ranbaxy Laboratories Limited (IN) | 2003-01-29 | — | — | EP | claimed |
| WO-2001066512-A1 | ONE-POT SYNTHESIS OF ALKYL 3-CYCLOPROPYLAMINO-2-[2,4-DIBROMO-3-(DIFLUOROMETHOXY)BENZOYL]-2-PROPENOATE AS A USEFUL INTERMEDIATE FOR ANTIBACTERIAL QUINOLONE MEDICAMENTS | RANBAXY LABORATORIES LIMITED (IN) | 2001-09-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267019-A1 | ONE-POT SYNTHESIS OF ALKYL 3-CYCLOPROPYLAMINO -2-[2,4-DIBROMO-3-(DIFLUROMETHOXY) BENZOYL]-2-PROPENOATE AS A USEFUL INTERMEDIATE FOR ANTIBACTERIAL QUINOLONE MEDICAMENTS | TET2, TET3, TET1 | POLB 282/4885HPGD 657/4885LMNA 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.